CD19
CD3型
癌症研究
慢性淋巴细胞白血病
白血病
T细胞
抗体
重组DNA
医学
抗原
嵌合抗原受体
双特异性抗体
淋巴瘤
化学
免疫学
单克隆抗体
生物化学
免疫系统
CD8型
基因
出处
期刊:PubMed
日期:2006-02-01
卷期号:8 (1): 62-8
被引量:4
摘要
Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
科研通智能强力驱动
Strongly Powered by AbleSci AI